Regen BioPharma Inc (RGBP)

[cvinvestor]

PPS of this stock is more perplexing as time goes on. Obviously, there has been scientific progress on several fronts of RGBP's pipeline this year and Q4 might bring further positive developments if FDA approves dCellVax for clinical trials based on RGBPs further data provided by Dr Kesari at legit labs, possible Orphan Drug status for HemaXellerate and an announcement of someone actually going to proceed with HemaXellerate's approval last year into human trials.

Beyond that, they have more data to proceed with development of NR2F6. Yet we sit at a lower PPS than when we began 2016.

I forget where share count was at when we began 2016, but it seems apparent that the way the company issues shares outweighs the influence of the scientific progress which unfortunately, only appears to confirm the theory that this company, for the foreseeable future, is all about sharing and spreading the opportunity of wealth within.

Just hope that at some point it changes. Several million shares traded this week on seemingly significant good news. Yet we are lower PPS. Next financials are going to be mighty interesting in regards to share distribution.